Early in the development of CAR-T therapies, researchers identified the B-cell maturation antigen (BCMA) as a promising target for the treatment of relapsed/refractory (R/R) multiple myeloma in addition to the CD19-directed CAR-Ts, which target B-cell malignancies. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.